153 related articles for article (PubMed ID: 11277535)
21. Last findings on dual inhibitors of abl and SRC tyrosine-kinases.
Schenone S; Manetti F; Botta M
Mini Rev Med Chem; 2007 Feb; 7(2):191-201. PubMed ID: 17305593
[TBL] [Abstract][Full Text] [Related]
22. Synthesis of echiguanine analogs and their ribofuranosyl glycosides that inhibit phosphatidylinositol 4-kinase.
Saito Y; Kato K; Umezawa K
Nucleic Acids Symp Ser; 1997; (37):13-4. PubMed ID: 9585975
[TBL] [Abstract][Full Text] [Related]
23. Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.
Wang Y; Mitchell-Ryan S; Raghavan S; George C; Orr S; Hou Z; Matherly LH; Gangjee A
J Med Chem; 2015 Feb; 58(3):1479-93. PubMed ID: 25602637
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and in vitro EGFR (ErbB1) tyrosine kinase inhibitory activity of 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines.
Kaspersen SJ; Sørum C; Willassen V; Fuglseth E; Kjøbli E; Bjørkøy G; Sundby E; Hoff BH
Eur J Med Chem; 2011 Dec; 46(12):6002-14. PubMed ID: 22018877
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
[TBL] [Abstract][Full Text] [Related]
26. Rational design of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones as a novel class of inhibitors of epidermal growth factor receptor (EGF-R) and Her2(p185(erbB)) tyrosine kinases.
Sun L; Cui J; Liang C; Zhou Y; Nematalla A; Wang X; Chen H; Tang C; Wei J
Bioorg Med Chem Lett; 2002 Aug; 12(16):2153-7. PubMed ID: 12127526
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
28. Structural factors contributing to the Abl/Lyn dual inhibitory activity of 3-substituted benzamide derivatives.
Horio T; Hamasaki T; Inoue T; Wakayama T; Itou S; Naito H; Asaki T; Hayase H; Niwa T
Bioorg Med Chem Lett; 2007 May; 17(10):2712-7. PubMed ID: 17376680
[TBL] [Abstract][Full Text] [Related]
29. Activity of 6-aryl-pyrrolo[2,3-d]pyrimidine-4-amines to Tetrahymena.
Kaspersen SJ; Sundby E; Charnock C; Hoff BH
Bioorg Chem; 2012 Oct; 44():35-41. PubMed ID: 22832269
[TBL] [Abstract][Full Text] [Related]
30. Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity.
Kaspersen SJ; Han J; Nørsett KG; Rydså L; Kjøbli E; Bugge S; Bjørkøy G; Sundby E; Hoff BH
Eur J Pharm Sci; 2014 Aug; 59():69-82. PubMed ID: 24769040
[TBL] [Abstract][Full Text] [Related]
31. Tyrosine kinase inhibitors. 2. Synthesis of 2,2'-dithiobis(1H-indole-3-alkanamides) and investigation of their inhibitory activity against epidermal growth factor receptor and pp60v-src protein tyrosine kinases.
Thompson AM; Fry DW; Kraker AJ; Denny WA
J Med Chem; 1994 Mar; 37(5):598-609. PubMed ID: 7510340
[TBL] [Abstract][Full Text] [Related]
32. Src-Abl tyrosine kinase chimeras: replacement of the adenine binding pocket of c-Abl with v-Src to swap nucleotide and inhibitor specificities.
Liu Y; Witucki LA; Shah K; Bishop AC; Shokat KM
Biochemistry; 2000 Nov; 39(47):14400-8. PubMed ID: 11087392
[TBL] [Abstract][Full Text] [Related]
33. Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.
Smaill JB; Showalter HD; Zhou H; Bridges AJ; McNamara DJ; Fry DW; Nelson JM; Sherwood V; Vincent PW; Roberts BJ; Elliott WL; Denny WA
J Med Chem; 2001 Feb; 44(3):429-40. PubMed ID: 11462982
[TBL] [Abstract][Full Text] [Related]
34. Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues.
Sundaramoorthi R; Shakespeare WC; Keenan TP; Metcalf CA; Wang Y; Mani U; Taylor M; Liu S; Bohacek RS; Narula SS; Dalgarno DC; van Schravandijk MR; Violette SM; Liou S; Adams S; Ram MK; Keats JA; Weigle M; Sawyer TK; Weigele M
Bioorg Med Chem Lett; 2003 Sep; 13(18):3063-6. PubMed ID: 12941334
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis and biological evaluation of novel 6-substituted pyrrolo [3,2-d] pyrimidine analogues as antifolate antitumor agents.
Tian C; Wang M; Han Z; Fang F; Zhang Z; Wang X; Liu J
Eur J Med Chem; 2017 Sep; 138():630-643. PubMed ID: 28711701
[TBL] [Abstract][Full Text] [Related]
36. Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
El-Moghazy SM; George RF; Osman EEA; Elbatrawy AA; Kissova M; Colombo A; Crespan E; Maga G
Eur J Med Chem; 2016 Nov; 123():1-13. PubMed ID: 27474918
[TBL] [Abstract][Full Text] [Related]
37. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
Arafa RK; Nour MS; El-Sayed NA
Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
[TBL] [Abstract][Full Text] [Related]
38. Potent and selective EGFR inhibitors based on 5-aryl-7H-pyrrolopyrimidin-4-amines.
Reiersølmoen AC; Aarhus TI; Eckelt S; Nørsett KG; Sundby E; Hoff BH
Bioorg Chem; 2019 Jul; 88():102918. PubMed ID: 30999245
[TBL] [Abstract][Full Text] [Related]
39. 4-Anilino-3-cyanobenzo[g]quinolines as kinase inhibitors.
Zhang N; Wu B; Wissner A; Powell DW; Rabindran SK; Kohler C; Boschelli F
Bioorg Med Chem Lett; 2002 Feb; 12(3):423-5. PubMed ID: 11814812
[TBL] [Abstract][Full Text] [Related]
40. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
Adel M; Serya RAT; Lasheen DS; Abouzid KAM
Bioorg Chem; 2018 Dec; 81():612-629. PubMed ID: 30248512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]